Kiniksa Pharmaceuticals International (NASDAQ:KNSA) CEO Sanj Patel Sells 22,544 Shares

Kiniksa Pharmaceuticals International, plc (NASDAQ:KNSA) CEO Sanj Patel sold 22,544 shares of the business’s stock in a transaction that occurred on Wednesday, April 29th. The shares were sold at an average price of $54.01, for a total value of $1,217,601.44. Following the completion of the transaction, the chief executive officer directly owned 431,904 shares in the company, valued at approximately $23,327,135.04. This trade represents a 4.96% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Kiniksa Pharmaceuticals International Stock Performance

Shares of KNSA opened at $53.78 on Friday. Kiniksa Pharmaceuticals International, plc has a 52-week low of $24.85 and a 52-week high of $54.31. The business’s 50 day moving average price is $46.40 and its two-hundred day moving average price is $43.12. The firm has a market cap of $4.12 billion, a PE ratio of 59.76 and a beta of 0.06.

Kiniksa Pharmaceuticals International (NASDAQ:KNSA) last issued its quarterly earnings results on Tuesday, April 28th. The company reported $0.27 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.18 by $0.09. Kiniksa Pharmaceuticals International had a return on equity of 13.72% and a net margin of 9.69%.The firm had revenue of $214.27 million for the quarter, compared to analyst estimates of $206.11 million. During the same period in the previous year, the firm earned $0.11 earnings per share. The company’s revenue was up 55.5% compared to the same quarter last year. Research analysts predict that Kiniksa Pharmaceuticals International, plc will post 1.17 EPS for the current fiscal year.

Analysts Set New Price Targets

A number of equities analysts have recently weighed in on the company. Zacks Research lowered Kiniksa Pharmaceuticals International from a “hold” rating to a “strong sell” rating in a research report on Friday, April 17th. Weiss Ratings reaffirmed a “hold (c)” rating on shares of Kiniksa Pharmaceuticals International in a research report on Tuesday, April 21st. Canaccord Genuity Group upped their target price on Kiniksa Pharmaceuticals International from $62.00 to $64.00 and gave the stock a “buy” rating in a research report on Wednesday. Jefferies Financial Group upped their target price on Kiniksa Pharmaceuticals International from $58.00 to $71.00 and gave the stock a “buy” rating in a research report on Tuesday. Finally, Wells Fargo & Company upped their target price on Kiniksa Pharmaceuticals International from $53.00 to $57.00 and gave the stock an “overweight” rating in a research report on Wednesday. Seven research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $60.86.

Institutional Investors Weigh In On Kiniksa Pharmaceuticals International

A number of institutional investors and hedge funds have recently bought and sold shares of KNSA. Qube Research & Technologies Ltd raised its position in Kiniksa Pharmaceuticals International by 277.8% in the 2nd quarter. Qube Research & Technologies Ltd now owns 888,364 shares of the company’s stock valued at $24,581,000 after buying an additional 653,236 shares during the last quarter. Rubric Capital Management LP raised its position in Kiniksa Pharmaceuticals International by 15.6% in the 2nd quarter. Rubric Capital Management LP now owns 3,909,806 shares of the company’s stock valued at $108,184,000 after buying an additional 526,567 shares during the last quarter. Cubist Systematic Strategies LLC raised its position in Kiniksa Pharmaceuticals International by 213.2% in the 2nd quarter. Cubist Systematic Strategies LLC now owns 657,475 shares of the company’s stock valued at $18,192,000 after buying an additional 447,536 shares during the last quarter. Spruce Street Capital LP purchased a new stake in Kiniksa Pharmaceuticals International in the 4th quarter valued at $17,943,000. Finally, SG Americas Securities LLC raised its position in Kiniksa Pharmaceuticals International by 288.6% in the 4th quarter. SG Americas Securities LLC now owns 541,396 shares of the company’s stock valued at $22,333,000 after buying an additional 402,078 shares during the last quarter. 53.95% of the stock is owned by hedge funds and other institutional investors.

Kiniksa Pharmaceuticals International News Roundup

Here are the key news stories impacting Kiniksa Pharmaceuticals International this week:

• Positive Sentiment: Q1 beat and raised guidance — Kiniksa reported $0.27 EPS vs. $0.18 consensus and revenue of $214.3M (≈+55.5% YoY); management raised FY‑2026 revenue guidance to $930M–$945M, improving near‑term revenue visibility. Read More.
• Positive Sentiment: Analyst upgrades/target raises — Multiple brokers lifted ratings and targets (examples: Jefferies to $71, Canaccord to $64, Citi to $60, Wedbush to $59, Wells Fargo to $57), signaling higher earnings/revenue expectations and encouraging flows. Read More.
• Positive Sentiment: Product momentum — ARCALYST reported strong net product revenue in Q1 and management increased 2026 expectations; this supports revenue durability and valuation expansion. Read More.
• Positive Sentiment: Pipeline catalysts ahead — KPL‑387 Phase 2 recurrent pericarditis data expected in 2H‑2026 with a planned Phase 3 start by year‑end; upcoming readouts could be material share‑price catalysts. Read More.
• Neutral Sentiment: Earnings materials available — Q1 slide deck and call transcript posted; useful for validating channel dynamics, margin assumptions and guidance drivers. Read More.
• Negative Sentiment: Large CEO selling — CEO Sanj K. Patel sold 483,654 shares on Apr. 28 (avg ~$51.86) and additional smaller tranches Apr. 29–30 under a pre‑arranged 10b5‑1 plan; this reduced his reported stake materially and may weigh on sentiment despite the plan. Read More.
• Negative Sentiment: Director sale — Director Barry D. Quart sold 13,099 shares (~$50.10 avg) under a 10b5‑1 plan, cutting his holding ~51%; insider selling can add short‑term pressure even when pre‑planned. Read More.

Kiniksa Pharmaceuticals International Company Profile

Kiniksa Pharmaceuticals International, Inc is a biopharmaceutical company focused on discovering, acquiring and developing therapeutics for patients suffering from lifethreatening and debilitating immune-mediated diseases. Founded in 2013 and headquartered in Lexington, Massachusetts, Kiniksa applies a patient-centric approach to build a diversified portfolio of marketed medicines and clinical-stage candidates targeting inflammation and immunology. The company’s core mission is to address complex conditions with significant unmet medical needs by advancing both novel and differentiated therapies.

The company’s lead marketed product is Ilaris (canakinumab), an interleukin-1β blocker licensed for the treatment of cryopyrin-associated periodic syndromes, systemic juvenile idiopathic arthritis, adult-onset Still’s disease and Schnitzler syndrome.